3 New Strong Buy Ratings from Top-Rated Analysts: 09/18/2025

Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:

• PagerDuty (PD) is back on the list — here’s why
• The real reason why Mirum Pharmaceuticals (MIRM) could outperform 
• Why GeneDX Holdings (WGS) just got a new street-high forecast 

P.S. Want more stocks chosen for you? Check out Zen Investor.

A note from our sponsors...

1. Mirum Pharmaceuticals (NASDAQ: MIRM)

Mirum Pharmaceuticals is a biopharma company that develops and commercializes treatments for rare liver diseases. MIRM has managed to capture the confidence of Wall Street analysts — the business enjoys a broad, promising pipeline, and our Artificial Intelligence rating suggests that it is a likely outperformer.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $73.52 — get current quote > 

Max 1-year forecast: $89.00 

Why we’re watching:

• MIRM enjoys broad, bullish coverage from Wall Street analysts. The stock currently has 3 Strong Buy ratings and 3 Buy ratings. See the ratings  
• The average 12-month price forecast for Mirum Pharmaceuticals shares is currently set at $83, and implies a healthy 11.69% upside.
• Jessica Fye of JP Morgan (a top 4% rated analyst) reiterated a Strong Buy rating on the stock after the company reported its Q2 2025 earnings, and increased her price target from $53 to $77.
• Fye said they responded to the print by "meaningfully" hiking their Livmarli forecasts because of the quarter's "strong" beat.
• Looking ahead at potential registrational data for volixibat in primary sclerosing cholangitis in Q2 of 2026, the analyst told readers that the stock has further upside if the trial is successful.
• MIRM shares rank in the 94th percentile of the equities that we track, giving them a Zen Rating of B.
• In terms of its Growth Component Grade rating, Mirum Pharmaceuticals ranks in the top 4% of stocks.
• Our Artificial Intelligence Component Grade rating uses a neural network trained on two decades of market data to evaluate stocks. In this category, MIRM also ranks in the top 4% of equities. (See all 7 Zen Component Grades here >)

2. GeneDX Holdings (NASDAQ: WGS) 

This company is in the business of precision medicine — genetic testing and whole exome sequencing, to be more exact. GeneDX is on the cutting edge of both diagnostics and personalized medicine — what’s more, both Wall Street analysts and company insiders seem convinced that there’s still plenty more room to grow for WGS.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $123.94 — get current quote > 

Max 1-year forecast: $140.00 

Why we’re watching:

• GeneDX Holdings shares currently have 4 Strong Buy ratings and 1 Hold rating. See the ratings  
• David Westenberg of Piper Sandler (a top 10% rated analyst)  recently doubled down on a Strong Buy rating on WGS, and increased his price target from $120 to a Street-high $140.
• Factors Westenberg cited for their continued bullish outlook on GeneDX Holdings included distinctive data assets, proven execution, and attractive development potential.
• The analyst also highlighted Genedx Holdings' capacity to establish new markets in the ever-changing rare illness testing industry and the company's strategic development into promising fields such as general pediatrics and the NICU. 
• Westenberg argued that Genedx Holdings is well-positioned because of its proactive strategy, differentiated data moat, and leadership, but they are aware of the execution risks associated with expanding into new areas and integrating acquisitions. 
• The stock has been doing well, but the analyst said it remains a good buy and recommended that readers buy it on any weakness.
• WGS shares rank in the top 11% of equities on the whole, giving them a Zen Rating of B, which has historically corresponded to an average annual return of 19.88%.
• GeneDX Holdings is also the 9th highest-rated stock in the Health Information Service industry, which has an Industry Rating of B.
• In the past 12 months, 23.25% of the insider transactions tied to WGS stock have been purchases. Couple that with positive analyst coverage, and it’s little wonder that the stock ranks in the 95th percentile with regard to Sentiment.
• However, Growth is WGS’ primary selling point — in terms of this Component Grade rating, it ranks in the top 2% of equities. (See all 7 Zen Component Grades here >)

3. PagerDuty (NYSE: PD) 

Are the long-forgotten pagers of the '90s making a comeback? No — but PD stock, which has been on a downward trajectory, just might. PagerDuty has been in the cloud-based incident management and operations business since 2009, and despite a challenging set of circumstances, growth expectations are quite high, and the company has the balance sheet to finance high-margin opportunities.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $16.21 — get current quote > 

Max 1-year forecast:  

Why we’re watching:

• Analyst coverage of PagerDuty is mixed — the stock currently has 2 Strong Buy ratings, 1 Buy rating, 3 Hold ratings, and 1 Sell rating. See the ratings  
• With that said, the average 12-month price forecast for PD shares, currently set at $18.43, paints a much more bullish picture, as it implies a 12.1% upside.  
• Canaccord Genuity researcher Kingsley Crane (a top 19% rated analyst) maintained a Strong Buy rating on the stock after the company reported its Q2 2026 earnings. Crane also decreased his price target from $21 to $19.
• Crane pointed to the quarter's "mixed" results, headlined by revenue just below the midpoint of guidance.
• The print reflected PagerDuty's ongoing GTM realignment against broad-based seat-based headwinds primarily among SMBs, but more recently among enterprise customers as well.
• That said, the announcement that Todd McNabb will step in as CRO should be well-received by investors, Crane predicted.
• PagerDuty is the 4th highest-rated stock in the App industry, which has an Industry Rating of B.
• PD currently ranks in the 97th percentile of the stocks that we track, giving it a Zen Rating of A, which has historically corresponded to an average annual return of 32.52%.
• Financials and Growth are PagerDuty’s biggest advantages — in these categories, the stock ranks in the top 10% and top 3% of stocks, respectively. (See all 7 Zen Component Grades here >)

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.